Research graph
References from PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
10.1016/j.ejca.2012.12.027 · 2013 · External reference
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005 · External reference
MGMT gene silencing and benefit from temozolomide in glioblastoma
10.1056/nejmoa043331 · 2005 · External reference
AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
10.1007/s12325-011-0007-3 · 2011 · External reference
A randomized trial of bevacizumab for newly diagnosed glioblastoma
10.1056/nejmoa1308573 · 2014 · External reference
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(14)70379-1 · 2014 · External reference
2010 Society for neuro-oncology annual meeting: a report of selected studies
10.1586/era.10.227 · 2011 · External reference
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
10.1200/jco.2008.17.5984 · 2009 · External reference
Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas
10.1038/onc.2010.249 · 2010 · External reference
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
10.1038/nature05236 · 2006 · External reference
PARP-1 protein expression in glioblastoma multiforme
10.4081/ejh.2012.e9 · 2012 · External reference
Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors
10.2174/187152010793498627 · 2010 · External reference
The potential of PARP inhibitors in neuro-oncology
10.2217/cns.12.13 · 2012 · External reference
“Replication-dependent radiosensitisation of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential
10.1016/j.ijrobp.2008.07.031 · 2008 · External reference
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA syntheses
10.1158/1535-7163.mct-05-0418 · 2006 · External reference
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
10.1007/s00280-013-2113-1 · 2013 · External reference
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
10.1093/annonc/mdv308 · 2015 · External reference
Poly(ADP-ribosyl)ation enzyme-1 as a target for neuroprotection in acute central nervous system injury
10.2174/1568007033482733 · 2003 · External reference
Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain
10.1667/rr2587.1 · 2011 · External reference
MGMT testing – the challenges for biomarker-based glioma treatment
10.1038/nrneurol.2014.100 · 2014 · External reference
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
10.1158/1078-0432.ccr-15-3153 · 2016 · External reference
